Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis.

G. F. Grauer, D. S. Greco, D. M. Getzy, Larry D Cowgill, S. L. Vaden, D. J. Chew, D. J. Polzin, J. A. Barsanti

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

A blinded, multicenter, prospective clinical trial assessed the effects of enalapril (EN) versus standard care in dogs with naturally occurring, idiopathic glomerulonephritis (GN). Twenty-nine adult dogs with membranous (n = 16) and membranoproliferative (n = 13) GN were studied. Dogs were randomly assigned to receive either EN (0.5 mg/kg PO q12-24h; n = 16) or placebo (n = 14) for 6 months (1 dog was treated first with the placebo and then with EN). All dogs were treated with low-dose aspirin (0.5-5 mg/kg PO q12-24h) and fed a commercial diet. At baseline, serum creatinine (SrCr), systolic blood pressure (SBP), and glomerular histologic grade were not different between groups, but the urine protein/creatinine ratio (UP/C) was greater in the EN group compared with the placebo group (8.7 +/- 4.4 versus 4.7 +/- 2.3). After 6 months of treatment, the change in UP/C from baseline was significantly different between groups (EN = -4.2 +/- 1.4 versus 1.9 +/- 0.9 in the placebo group). When data were adjusted for changes in SrCr (SrCr X UP/C) a similar significant reduction was noted ( 2.2 +/- 15.2 versus 8.4 +/- 10.1). The change in SBP after 6 months of treatment also was significantly different between groups (EN = -12.8 +/- 27.3 versus 5.9 +/- 21.5 mm Hg in the placebo group). Response to treatment was categorized as improvement (assigned a value of 2), no progression (assigned a value of 1), and progression (assigned a value of 0). Response was significantly better in the EN group (1.4 +/- 0.8) compared with the placebo group (0.3 +/- 0.5). These results suggest that EN treatment is beneficial in dogs with naturally occurring idiopathic GN.

Original languageEnglish (US)
Pages (from-to)526-533
Number of pages8
JournalJournal of veterinary internal medicine / American College of Veterinary Internal Medicine
Volume14
Issue number5
StatePublished - Sep 2000

Fingerprint

glomerulonephritis
Enalapril
Glomerulonephritis
creatinine
placebos
Canidae
Placebos
Creatinine
dogs
Dogs
urine
systolic blood pressure
Blood Pressure
Urine
Therapeutics
aspirin
proteins
Serum
prospective studies
Proteins

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis. / Grauer, G. F.; Greco, D. S.; Getzy, D. M.; Cowgill, Larry D; Vaden, S. L.; Chew, D. J.; Polzin, D. J.; Barsanti, J. A.

In: Journal of veterinary internal medicine / American College of Veterinary Internal Medicine, Vol. 14, No. 5, 09.2000, p. 526-533.

Research output: Contribution to journalArticle

Grauer, G. F. ; Greco, D. S. ; Getzy, D. M. ; Cowgill, Larry D ; Vaden, S. L. ; Chew, D. J. ; Polzin, D. J. ; Barsanti, J. A. / Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis. In: Journal of veterinary internal medicine / American College of Veterinary Internal Medicine. 2000 ; Vol. 14, No. 5. pp. 526-533.
@article{25a5071c4cfd41a2a098652eff3f5a06,
title = "Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis.",
abstract = "A blinded, multicenter, prospective clinical trial assessed the effects of enalapril (EN) versus standard care in dogs with naturally occurring, idiopathic glomerulonephritis (GN). Twenty-nine adult dogs with membranous (n = 16) and membranoproliferative (n = 13) GN were studied. Dogs were randomly assigned to receive either EN (0.5 mg/kg PO q12-24h; n = 16) or placebo (n = 14) for 6 months (1 dog was treated first with the placebo and then with EN). All dogs were treated with low-dose aspirin (0.5-5 mg/kg PO q12-24h) and fed a commercial diet. At baseline, serum creatinine (SrCr), systolic blood pressure (SBP), and glomerular histologic grade were not different between groups, but the urine protein/creatinine ratio (UP/C) was greater in the EN group compared with the placebo group (8.7 +/- 4.4 versus 4.7 +/- 2.3). After 6 months of treatment, the change in UP/C from baseline was significantly different between groups (EN = -4.2 +/- 1.4 versus 1.9 +/- 0.9 in the placebo group). When data were adjusted for changes in SrCr (SrCr X UP/C) a similar significant reduction was noted ( 2.2 +/- 15.2 versus 8.4 +/- 10.1). The change in SBP after 6 months of treatment also was significantly different between groups (EN = -12.8 +/- 27.3 versus 5.9 +/- 21.5 mm Hg in the placebo group). Response to treatment was categorized as improvement (assigned a value of 2), no progression (assigned a value of 1), and progression (assigned a value of 0). Response was significantly better in the EN group (1.4 +/- 0.8) compared with the placebo group (0.3 +/- 0.5). These results suggest that EN treatment is beneficial in dogs with naturally occurring idiopathic GN.",
author = "Grauer, {G. F.} and Greco, {D. S.} and Getzy, {D. M.} and Cowgill, {Larry D} and Vaden, {S. L.} and Chew, {D. J.} and Polzin, {D. J.} and Barsanti, {J. A.}",
year = "2000",
month = "9",
language = "English (US)",
volume = "14",
pages = "526--533",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis.

AU - Grauer, G. F.

AU - Greco, D. S.

AU - Getzy, D. M.

AU - Cowgill, Larry D

AU - Vaden, S. L.

AU - Chew, D. J.

AU - Polzin, D. J.

AU - Barsanti, J. A.

PY - 2000/9

Y1 - 2000/9

N2 - A blinded, multicenter, prospective clinical trial assessed the effects of enalapril (EN) versus standard care in dogs with naturally occurring, idiopathic glomerulonephritis (GN). Twenty-nine adult dogs with membranous (n = 16) and membranoproliferative (n = 13) GN were studied. Dogs were randomly assigned to receive either EN (0.5 mg/kg PO q12-24h; n = 16) or placebo (n = 14) for 6 months (1 dog was treated first with the placebo and then with EN). All dogs were treated with low-dose aspirin (0.5-5 mg/kg PO q12-24h) and fed a commercial diet. At baseline, serum creatinine (SrCr), systolic blood pressure (SBP), and glomerular histologic grade were not different between groups, but the urine protein/creatinine ratio (UP/C) was greater in the EN group compared with the placebo group (8.7 +/- 4.4 versus 4.7 +/- 2.3). After 6 months of treatment, the change in UP/C from baseline was significantly different between groups (EN = -4.2 +/- 1.4 versus 1.9 +/- 0.9 in the placebo group). When data were adjusted for changes in SrCr (SrCr X UP/C) a similar significant reduction was noted ( 2.2 +/- 15.2 versus 8.4 +/- 10.1). The change in SBP after 6 months of treatment also was significantly different between groups (EN = -12.8 +/- 27.3 versus 5.9 +/- 21.5 mm Hg in the placebo group). Response to treatment was categorized as improvement (assigned a value of 2), no progression (assigned a value of 1), and progression (assigned a value of 0). Response was significantly better in the EN group (1.4 +/- 0.8) compared with the placebo group (0.3 +/- 0.5). These results suggest that EN treatment is beneficial in dogs with naturally occurring idiopathic GN.

AB - A blinded, multicenter, prospective clinical trial assessed the effects of enalapril (EN) versus standard care in dogs with naturally occurring, idiopathic glomerulonephritis (GN). Twenty-nine adult dogs with membranous (n = 16) and membranoproliferative (n = 13) GN were studied. Dogs were randomly assigned to receive either EN (0.5 mg/kg PO q12-24h; n = 16) or placebo (n = 14) for 6 months (1 dog was treated first with the placebo and then with EN). All dogs were treated with low-dose aspirin (0.5-5 mg/kg PO q12-24h) and fed a commercial diet. At baseline, serum creatinine (SrCr), systolic blood pressure (SBP), and glomerular histologic grade were not different between groups, but the urine protein/creatinine ratio (UP/C) was greater in the EN group compared with the placebo group (8.7 +/- 4.4 versus 4.7 +/- 2.3). After 6 months of treatment, the change in UP/C from baseline was significantly different between groups (EN = -4.2 +/- 1.4 versus 1.9 +/- 0.9 in the placebo group). When data were adjusted for changes in SrCr (SrCr X UP/C) a similar significant reduction was noted ( 2.2 +/- 15.2 versus 8.4 +/- 10.1). The change in SBP after 6 months of treatment also was significantly different between groups (EN = -12.8 +/- 27.3 versus 5.9 +/- 21.5 mm Hg in the placebo group). Response to treatment was categorized as improvement (assigned a value of 2), no progression (assigned a value of 1), and progression (assigned a value of 0). Response was significantly better in the EN group (1.4 +/- 0.8) compared with the placebo group (0.3 +/- 0.5). These results suggest that EN treatment is beneficial in dogs with naturally occurring idiopathic GN.

UR - http://www.scopus.com/inward/record.url?scp=0034277440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034277440&partnerID=8YFLogxK

M3 - Article

C2 - 11012117

AN - SCOPUS:0034277440

VL - 14

SP - 526

EP - 533

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 5

ER -